Antonio Fontelonga
NPI 1437164100 · Hematology & Oncology Physician · Reno, NV
Enrolled with Medicare as Practitioner - Hematology/Oncology · source: CMS PECOS Public Provider Enrollment (2026.04.01)
Provider details
- NPI number
- 1437164100
- Entity type
- Individual
- Primary specialty
- Hematology & Oncology PhysicianAllopathic & Osteopathic Physicians
- Sex
- Male
- Sole proprietor
- No
- License
- 100667 (NV)
Specialties & taxonomies
Allopathic & Osteopathic Physicians
Profile Score
A profile completeness & documented-activity index — NOT a quality, outcomes, or patient-satisfaction rating.
- Registry tenure25% of score
19 yrs in NPPES registry
- Profile completeness25% of score
100% of core fields populated
- Practice footprint15% of score
1 documented practice location
- Medicare service volume (vs. specialty peers)25% of score
1,629 Medicare services, 2024 (ranked within specialty)
- Open Payments transparency10% of score
Has Open Payments disclosures (2024)
Medicare volume is ranked against active providers in the same specialty. Signals a provider has no public data for (e.g. Medicare claims) are left out of the score entirely — never counted as zero — so providers without that data are not penalized. See the full formula and weights in our .
What this provider does (Medicare)
Based on Medicare fee-for-service claims, 2024; not all care is captured.
| Service (HCPCS) | Medicare services | Typical Medicare-allowed (2024) |
|---|---|---|
| Established Patient Office Or Other Outpatient Visit With Moderate Level of Decision Making, If Using Time, 30 Minutes Or More99214 | 438 | $122 |
| Insertion of Needle Into Vein for Collection of Blood Sample36415 | 328 | $9 |
| Injection of Additional New Drug Or Substance Into Vein96375 | 288 | $15 |
| Injection of Drug Or Substance Under Skin Or Into Muscle96372 | 226 | $14 |
| Administration of Chemotherapy Into Vein, 1 Hour Or Less96413 | 167 | $122 |
| Irrigation of Implanted Venous Access Drug Delivery Device96523 | 78 | $23 |
What this provider prescribes (Medicare Part D)
Top drugs by Medicare Part D claim volume, 2024 · 10 distinct drugs on file.
| Drug | Part D claims (2024) | Beneficiaries |
|---|---|---|
| Anastrozole | 88 | 29 |
| Hydroxyurea | 41 | — |
| Levothyroxine Sodium | 29 | — |
| Abiraterone Acetate | 26 | — |
| Letrozole | 23 | — |
| Exemestane | 18 | — |
| Tamoxifen Citrate | 18 | — |
| Prednisone | 15 |
Transparency — industry payments
Based on CMS Open Payments, 2024; not all care is captured.
$1,446 across 62 records (Open Payments 2024)
Open Payments discloses payments and transfers of value (meals, travel, consulting, research, royalties) from drug and device makers to providers. This is a transparency signal, not a verdict — such payments are legal and common, and their presence is neither an endorsement nor a criticism. Source: CMS Open Payments, program year 2024.
Practice location
Mailing address
Registry dates
- Enumerated
- 2006-07-30
- Last updated
- 2014-11-06
Source: CMS NPPES Data Dissemination (June 2026). NPI Central is not affiliated with CMS. Data is provided as-is from the public registry.